AQP9 and rheumatoid arthritis: There is no overlap between the final gene panels of CD and RA regarding the responder versus non-responder comparison, but AQP9 and TNFAIP6 overlapped regarding the baseline versus week 2 comparisons, which account for the effects of therapy.